Waverley Pharma Inc V.WAVE

Healthcare Biotechnology

Waverley Pharma Inc. is a biopharmaceutical company engaged in the research, development, and commercialization of human therapeutics focused on oncology. Its primary focus is the PARP-1 program and secondary focus is the generic oncology injectable market in European Union, the United Kingdom (UK) and North America. It has entered into a license, manufacture, supply, marketing and distribution agreement with Reliance Life Sciences Private Limited, which has granted it an exclusive territorial license to market and sell capecitabine in the UK and Germany as well as a non-exclusive territorial license to market and sell temozolomide and erlotinib in the UK. Its generic oncology products include bortezomib and pemetrexed. Bortezomib is an injectable generic chemotherapy drug, developed for the treatment of multiple myeloma and mantle cell lymphoma. Pemetrexed is an injectable generic chemotherapy drug, developed for the treatment of non-small cell lung cancer and pleural mesothelioma.

TSXV:WAVE - Post by User

Waverley Pharma Inc > Lithium demand is projected to...

<< Previous

Bullboard Posts

Next >>

Post by rustdoteson Jul 30, 2020 12:40pm

56 Views

Post# 31344532

Lithium demand is projected to...

Lithium was struggling with an ongoing supply deficit. However, the lithium supply crunch is back. (The comeback is always better than the setback)

To give you an idea of how much supply the world may need, consider this.

“The production of minerals such as graphite, lithium and cobalt could increase by nearly 500 percent by 2050” to meet demands for new technologies, including EVs, according to The World Bank, as noted by Forbes.

<< Previous

Bullboard Posts

Next >>

BlackBerry partners with Avathon to enhance critical event management with AI